How the Ozempic gold rush is causing 'deeply concerning' shortage for diabetes patients

The unprecedented demand for GLP-1 medicines, fuelled by their remarkable ability to help patients shed up to 20% of body weight, has been nothing short of explosive.

Related Keywords

United Kingdom ,Denmark ,Danish ,Michael Kyle ,Lars Fruergaard ,Eli Lilly ,Sarita Menon ,Adrian Sanders ,Diabetes Global Network ,Novo Nordisk ,United Kingdom Department Of Health ,Parliamentary Diabetes Global Network ,Pharmacist Network ,Diabetes United ,Bio Pharma ,United Kingdom Department ,Social Care ,Markets Amp Regulations ,Pipelines ,Emerging Markets ,Obesity ,Diabetes ,